XBI Trading Analysis - 11/20/2026 02:34 PM โ€” TRU-SENTIMENT

XBI (State Street SPDR S&P Biotech ETF) at $141.86. True Sentiment Bearish, delta 40-60 call 8% / put 92%, call $274,220 vs put $3,108,080. RSI 35.9.

TRU-SENTIMENT ยท DeltaNeutral

XBI Trading Analysis - 11/20/2026 02:34 PM โ€” TRU-SENTIMENT

Options chain ยท Stock chart ยท Baseline chart

XBI (State Street SPDR S&P Biotech ETF) at $141.86. True Sentiment Bearish, delta 40-60 call 8% / put 92%, call $274,220 vs put $3,108,080. RSI 35.9.

Symbol
XBI
Price
$141.86
Article bias (separate from True Sentiment)
bearish
Conviction
medium
Published
2026-11-20 14:34:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

Methodology: Delta 40-60 options only. Timestamp 2026-11-20 14:33.

Call Dollar Volume: $274,220.00 (8.1%) Put Dollar Volume: $3,108,080.00 (91.9%) Total: $3,382,300.00

Call contracts 373 vs put contracts 4,804. Sentiment: Bearish. Pure directional positioning shows overwhelming put conviction (91.9% put dollar vol), suggesting near-term downside expectations. This aligns with technical weakness; no divergence between sentiment and price action.

Note: Options flow is the only sentiment source; no live X posts retrieved.

Key Statistics: XBI

$141.52 -2.04%
52-Week Range
$113.57 - $169.89
Market Cap
$9.91B
P/E (TTM)
N/A
PEG Ratio
N/A
Beta
1.01
Next Earnings
N/A
Avg Volume
$7.79M
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

Market cap$9.91B
Shares outstanding70.0M

Dividend

Dividend yield0.38%
Annual dividend$0.54
Ex-dividend date2026-06-22

Risk & range

Beta1.01
52-week low$113.57
52-week high$169.89
Historical volatility39.2%

Ownership & trading

Institutional ownership7.7%
Average daily volume8.7M sh

Reported figures; no analyst estimates.


๐Ÿ“ˆ Analysis

News Headlines & Context

The following items use general knowledge for context only and are separate from the data-driven analysis below:

  • Biotech sector ETFs like XBI have faced pressure amid broader risk-off sentiment in small-cap healthcare ahead of year-end.
  • Recent FDA clinical trial setbacks across several small-cap biotech names have weighed on sector sentiment.
  • Speculation around 2027 healthcare budget cuts and drug-pricing reform has increased uncertainty for speculative biotech equities.
  • XBI typically exhibits high beta to interest-rate expectations; recent firming in yields has pressured the group.
  • No XBI-specific earnings catalyst exists (ETF structure), but constituent volatility remains elevated into December.

Context: Headlines reflect a bearish macro/biotech backdrop that aligns with the embedded options flow showing 91.9% put dollar volume conviction and weak technicals (RSI 35.86, price below all major SMAs).

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for XBI:

  • Trailing EPS: null; Forward EPS: null; Trailing PE: null; Forward PE: null; PEG Ratio: null โ€” valuation multiples not available for this ETF structure.
  • Revenue Growth: null; Total Revenue: null; Profit Margins: null; Return on Equity: null; Debt to Equity: null; Free Cashflow: null โ€” not disclosed in data.
  • Market Cap: $9,906,400,000.00; Shares Outstanding: 70,000,000.00; Dividend Yield: 0.38%; Dividend Rate: $0.54; Ex-Dividend: 2026-06-22.
  • Beta: 1.01 (market-like systemic risk); 52-Week High: $169.89; 52-Week Low: $113.57.
  • Institutional Percent: 7.71% (low sponsorship vs typical large ETFs).
  • Average Volume: 8,728,000.00; Historical Volatility: 39.24%.
  • Analyst Consensus / Target Mean Price: null (no analyst opinion data).

Fundamental takeaway: As an ETF, XBI carries no reportable corporate margins or EPS. The lack of valuation multiples and low institutional holding (7.71%) coincide with the weak technical and bearish options flow, showing no fundamental divergence to offset the negative technical picture.

Current Market Position

Current price per indicators: $144.47 (as of 2026-11-19 close). Minute bars show 2026-11-20 14:05 last price $141.86, down from 2026-11-19 09:30 open $145.38. Recent daily action: 2026-11-19 close $144.47 on volume 11,993,864 vs 20-day avg 7,390,593 โ€” high-volume decline.

Intraday momentum (minute bars): Early 2026-11-19 traded up to $146.85 then faded; by 2026-11-20 13:45โ€“14:05 ranged $141.31โ€“$142.14, closing near $141.86, showing persistent downside drift.

Support (Bollinger Lower)
$143.33
Support (30d Low)
$143.24
Resistance (SMA 5)
$146.22
Resistance (SMA 20)
$152.18
Resistance (SMA 50)
$153.08

Technical Analysis

Technical Indicators

Current Price
$144.47
SMA 5
$146.22
SMA 20
$152.18
SMA 50
$153.08
RSI (14)
35.86
MACD
-2.07
MACD Signal
-1.65
MACD Hist
-0.41
BB Lower
$143.33
BB Middle
$152.18
BB Upper
$161.04
ATR 14
$5.17
30d High
$160.29
30d Low
$143.24

Price is below SMA 5 ($146.22), SMA 20 ($152.18), and SMA 50 ($153.08) โ€” bearish alignment, no bullish crossovers. RSI 35.86 indicates weak momentum nearing oversold but not extreme. MACD (-2.07) below signal (-1.65), histogram -0.41 confirms bearish momentum. Bollinger Bands: price at $144.47 sits just above lower band $143.33 (expansion, not squeeze). 30-day range: price near bottom (low $143.24, high $160.29), only ~1.7% above 30d low.

True Sentiment Analysis (Delta 40-60 Options)

Methodology: Delta 40-60 options only. Timestamp 2026-11-20 14:33.

Call Dollar Volume: $274,220.00 (8.1%) Put Dollar Volume: $3,108,080.00 (91.9%) Total: $3,382,300.00

Call contracts 373 vs put contracts 4,804. Sentiment: Bearish. Pure directional positioning shows overwhelming put conviction (91.9% put dollar vol), suggesting near-term downside expectations. This aligns with technical weakness; no divergence between sentiment and price action.

Note: Options flow is the only sentiment source; no live X posts retrieved.

Key Price Levels (Observational Only)

Support (BB Lower / 30d Low)
$143.24โ€“$143.33
Resistance (SMA 5)
$146.22
Resistance (SMA 20 / BB Mid)
$152.18
Resistance (SMA 50)
$153.08

Interactive charts load with JavaScript. This text is the crawlable summary.